Status:
UNKNOWN
Immunisation Status and Safety of Vaccines in Italian MS Patients
Lead Sponsor:
Monica Ulivelli
Collaborating Sponsors:
Fondazione Italiana Sclerosi Multipla
San Luigi Gonzaga Hospital
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Multiple sclerosis (MS) patients are more susceptible to infections than the general population in relation to some specific therapies or increasing disability. Clearly, the use of immuno-suppressant/...
Detailed Description
The different available treatments for MS influence the immune system in distinct ways and, therefore, may lead to specific infectious risks. Whereas immunomodulating therapies have no impact on infec...
Eligibility Criteria
Inclusion
- diagnosis of RR-MS according to the 2010 Polman's diagnostic criteria \[Polman 2011\] or the 2017 revision of the McDonald criteria for the prospective cohort \[Thompson 2018\]
- written informed consent must be obtained before the enrolment
Exclusion
- clinically isolated syndrome (CIS) and progressive MS forms
- unavailability or unreliability of medical records
Key Trial Info
Start Date :
March 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2023
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04300868
Start Date
March 20 2019
End Date
March 31 2023
Last Update
November 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
university of Siena
Siena, SI, Italy, 53100